Precision medicine revolutionizes cancer care, empowering patients with personalized insights and targeted therapies while ...

Key Points Surrozen reported GAAP EPS of $2.55 for Q2 2025, exceeding expectations by $3.66 per share (GAAP) due to significant one-time and non-cash gains. Surrozen recorded $1.0 million in research ...

This piece discusses the past, present, and future of the patient-provider relationship, including the trend toward ...

Knowable Magazine reports that studying dogs' cancers offers insights into human cancer, due to similar pathways and faster ...

Over the past two centuries, vaccines have been critical for preventing infectious diseases. The World Health Organization ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head-to-head trials.

Here are five ways AI is reshaping healthcare in 2025, through the lens of hiring, recruitment and workforce planning.

GAAP net loss per share was $(11.29) for Q2 2025, missing the consensus GAAP EPS estimate of $(4.62) by a wide margin, mainly due to a $17.0 million up-front license fee. NextCure advanced both its ...

Curreen Capital breaks down Fortrea’s struggles and turnaround potential. Learn why this CRO stock might rebound and what it means for long-term investors.

Claiming it wants to cut waste, the Trump administration has terminated grants for research testing ways to save the health ...

Hundreds of peer-reviewed studies on marijuana and its components have been published in the first seven months of 2025, ...